Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Novacyt ( (FR:ALNOV) ) has shared an update.
Novacyt reported February trading activity under its French law-governed liquidity agreement with Invest Securities, which bought 12,019 and sold 12,016 ordinary shares during the month at prices between €0.39 and €0.43. As a result, the company held 113,918 treasury shares at month-end, which are non-voting and non-dividend bearing.
The diagnostics group confirmed that its total share capital stands at 70,626,248 ordinary shares, a figure shareholders should use for calculating regulatory disclosure thresholds under French rules and the company’s articles. The update also reiterates that Novacyt remains outside the UK’s Financial Conduct Authority transparency regime, reflecting its primary regulatory alignment with the French market.
Novacyt additionally outlined key terms of the liquidity agreement, under which Invest Securities independently provides share liquidity and may repurchase up to 10% of the company’s share capital at a maximum price of €5.00 per share, as approved by shareholders until late 2026. Shares bought under this programme may be cancelled or held in treasury, giving the company flexibility in capital management while aiming to stabilise trading conditions for investors.
More about Novacyt
Novacyt S.A. is an international molecular diagnostics company listed on Euronext Growth in Paris and AIM in London, providing integrated technologies and services primarily focused on genomic medicine. It develops, manufactures and commercialises molecular assays, PCR instrumentation and DNA sample preparation platforms for human and animal health, agriculture and environmental testing, serving clinical, research and pharmaceutical customers in over 65 countries.
For an in-depth examination of ALNOV stock, go to TipRanks’ Overview page.